Hunter C. Smith - 10 Feb 2026 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Reporting relationship: Chief Financial Officer
Issuer ticker: RYTM
Reported as of: 10 Feb 2026
Net transaction value: -$708,576
SEC form: 4
Accepted by SEC: 12 Feb 2026, 20:56:57 UTC
Prior SEC filing: 06 Feb 2026
Next SEC filing: 19 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Stephen Vander Stoep, attorney-in-fact for Hunter C. Smith

Key filing fact

Hunter C. Smith filed Form 4 for RHYTHM PHARMACEUTICALS, INC. (RYTM) on 12 Feb 2026.

Key facts

This page summarizes Hunter C. Smith's Form 4 filing for RHYTHM PHARMACEUTICALS, INC. (RYTM).
12 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 12 Feb 2026, 20:56.

Change

Previous filing in this sequence was filed on 06 Feb 2026.
Current net transaction value: -$708,576.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001636385 Primary reporting owner

Smith Hunter C

Relationship: Chief Financial Officer
Address: C/O RHYTHM PHARMACEUTICALS, INC., 222 BERKELEY STREET, 12TH FLOOR, BOSTON
Signature: /s/ Stephen Vander Stoep, attorney-in-fact for Hunter C. Smith
Signature date: 12 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RYTM transaction

Common Stock

Sale

Transaction value: $196,380
Shares: -1,913
Change %: -1.5%
Price: $102.66
Shares after: 123,624
Date: 10 Feb 2026
Ownership: Direct
Footnotes: F1, F2

RYTM transaction

Common Stock

Sale

Transaction value: $72,574
Shares: -700
Change %: -0.57%
Price: $103.68
Shares after: 122,924
Date: 10 Feb 2026
Ownership: Direct
Footnotes: F1, F3

RYTM transaction

Common Stock

Sale

Transaction value: $10,476
Shares: -100
Change %: -0.08%
Price: $104.76
Shares after: 122,824
Date: 10 Feb 2026
Ownership: Direct
Footnotes: F1

RYTM transaction

Common Stock

Sale

Transaction value: $222,906
Shares: -2,266
Change %: -1.8%
Price: $98.37
Shares after: 120,558
Date: 11 Feb 2026
Ownership: Direct
Footnotes: F1, F4

RYTM transaction

Common Stock

Sale

Transaction value: $39,775
Shares: -400
Change %: -0.33%
Price: $99.44
Shares after: 120,158
Date: 11 Feb 2026
Ownership: Direct
Footnotes: F1, F5

RYTM transaction

Common Stock

Sale

Transaction value: $10,085
Shares: -100
Change %: -0.08%
Price: $100.85
Shares after: 120,058
Date: 11 Feb 2026
Ownership: Direct
Footnotes: F1, F6

RYTM transaction

Common Stock

Sale

Transaction value: $28,109
Shares: -292
Change %: -0.24%
Price: $96.26
Shares after: 119,766
Date: 12 Feb 2026
Ownership: Direct
Footnotes: F1, F7

RYTM transaction

Common Stock

Sale

Transaction value: $39,069
Shares: -400
Change %: -0.33%
Price: $97.67
Shares after: 119,366
Date: 12 Feb 2026
Ownership: Direct
Footnotes: F1, F8

RYTM transaction

Common Stock

Sale

Transaction value: $79,192
Shares: -800
Change %: -0.67%
Price: $98.99
Shares after: 118,566
Date: 12 Feb 2026
Ownership: Direct
Footnotes: F1, F9

RYTM transaction

Common Stock

Sale

Transaction value: $10,010
Shares: -100
Change %: -0.08%
Price: $100.10
Shares after: 118,466
Date: 12 Feb 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RYTM transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +25,000
Change %
Price: $0.000000
Shares after: 25,000
Date: 11 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price
Footnotes: F10, F11

RYTM transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +37,500
Change %
Price: $0.000000
Shares after: 37,500
Date: 11 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 37,500
Exercise price: $98.47
Footnotes: F12

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 12 footnotes

Footnote F1

The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025.

Footnote F2

The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $$102.09 to $103.02 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $103.23 to $103.98 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F4

The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $97.80 to $98.79 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F5

The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $98.89 to $99.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F6

The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.49 to $100.98 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F7

The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $96.04 to $96.58 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F8

The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $97.18 to $97.85 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F9

The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $98.54 to $99.40 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F10

Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Footnote F11

The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date.

Footnote F12

The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.